Navigation Links
XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced that on January 27, 2009 it received a Staff Determination Letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that the staff of Nasdaq's Listing Qualifications Department determined, using its discretionary authority under Nasdaq Marketplace Rule 4300, that the Company's American Depository Shares ("ADRs") would be delisted from Nasdaq. The Letter further stated that Nasdaq would suspend trading in the Company's ADRs at the opening of trading on February 5, 2009 and then file a Form 25-NSE with the Securities and Exchange Commission ("SEC") to deregister the Company's ADRs, unless the Company appeals Nasdaq's delisting determination. Nasdaq's determination to delist the ADRs was based on Nasdaq's belief that the Company was a public shell and that the Company does not meet the stockholder's equity requirement or any of its alternatives.

The Letter also indicated that, in accordance with the procedures set out in Marketplace Rule 4800 Series, the Company would have seven (7) calendar days, or until February 3, 2009, to appeal the delisting from Nasdaq to a Listing Qualifications Panel. At this time, the Company does plan to appeal the delisting from Nasdaq. There can be no assurance that the appeal will be successful.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Ardelyx, ... biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic ... quarter 2014 financial results on Thursday, November 6, ... will host a live conference call and webcast ... results and provide a business update. ...
(Date:10/30/2014)... Rancho BioSciences , the scientific ... curated public data source TCGA for several ... data is now available for other oncology groups. ... internal data sources for their Pharma, Government and academic ... data that becomes more easily accessible. Rancho advises ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Grace Century portfolio ... James A. Manganello, Chairman of the Board, to the ... The appointment was made by the Ministry of Health ... 24th, 2014. , More than a year after ... Bill , Prime Minister Perry Christie said the government has ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2
... 20 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Inc. (Ibis), has been awarded four new,government contracts ... detection,and identification of microbial threat agents for biodefense ... of Homeland Security,Science and Technology Directorate (DHS-S&T) and ...
... Retrieving material for composting from open dumps across the ... mountains of waste, according to researchers in India, writing ... Technology and Management. , These days we in the ... kitchen waste. However, not everyone has a compost bin ...
... Coulter,Inc. (NYSE: BEC ), a leading developer, ... innovate complex biomedical testing,announced today that Charles Slacik, ... will present at the 2007 UBS Global,Life Sciences ... p.m.,(EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
Cached Biology Technology:Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development 2Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development 3Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development 4Landfill mining reduces environmental impact of growing waste 2Beckman Coulter to Present at the UBS Global Life Sciences Conference 2
(Date:10/28/2014)... awards to expand the Office of Rare Diseases ... Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research ... at 22 consortia will work with 98 patient ... new treatments for patients with rare diseases. The ... fiscal 2014 funding from NIH. , Rett syndrome, ...
(Date:10/27/2014)... a scientific one-two punch with a pair of papers ... sticky ends. , Collagen is the most common protein ... fibrous tissues that support cells and hold organs together. ... for tissue engineering and cosmetic and reconstructive medicine. , ... synthetic collagen for a decade, teasing out the details ...
(Date:10/27/2014)... Recent breakthroughs may pave the way for vaccines ... helminths. These flatworms, including tapeworms that cause hydatid ... (schistosomes), infect more than 300 million people and ... due to chronic illness and death each year. ... microbiology, immunology, and tropical medicine, and scientific director ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3GW researcher adapting breakthrough technologies to combat parasitic worm infections 2
... of hatchery-raised young salmonids are released into Swedish rivers ... Butthese fish generally survive poorly in the wild. Researchers ... young fish get too crowded at the hatchery. ... million euro to a Swedish/Nordic research project. The goal ...
... of University of Kansas researchers working with Chinese colleagues have ... years ago in China. This is the first report of ... "This thing is a venomous bird for all intents and ... paleontology at the Natural History Museum and Biodiversity Institute. "It ...
... drug-resistant form of the deadly H5N1 avian influenza is a nightmare ... study published this week (Dec. 21) in the Proceedings of ... a new compound, one on the threshold of final testing in ... than the antiviral drug best known by the trade name Tamiflu. ...
Cached Biology News:Hatchery-raised salmon too crowded 2Poisonous prehistoric 'raptor' discovered by research team from Kansas and China 2Compound found to safely counter deadly bird flu 2